Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marina Goldis

Pediatrics Brooklyn, NY Medical Doctor

NPI 1457601460 CMS profile 831609

103 Quentin Rd, Fl2, Ste D, Brooklyn, NY 11223

Open in the dashboard

General payments

$8,611

393 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marina Goldis of Brooklyn, NY is reported in the CMS Open Payments database as having received $8,611 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $597 25
2024 General $945 41
2023 General $1,446 60
2022 General $1,529 70
2021 General $1,589 81
2020 General $1,039 53
2019 General $1,466 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marina Goldis
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Marina Goldis were reported at $597. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Marina Goldis Pediatrics median Middle half National median
2019 $1,466 $86 $31–$183 $163
2020 $1,039 $49 $22–$110 $114
2021 $1,589 $68 $27–$158 $132
2022 $1,529 $77 $30–$173 $149
2023 $1,446 $88 $33–$190 $160
2024 $945 $94 $34–$206 $164
2025 $597 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $964 45 payments
  2. Mannkind Corporation $820 48 payments
  3. Amneal Pharmaceuticals LLC $791 31 payments
  4. Novo Nordisk Inc $604 27 payments
  5. Arbor Pharmaceuticals, Inc. $466 26 payments
  6. CutisPharma, Inc. $452 17 payments
  7. Xeris Pharmaceuticals, Inc. $374 20 payments
  8. Horizon Therapeutics plc $346 6 payments
  9. Dexcom, Inc. $338 23 payments
  10. Amgen Inc. $329 8 payments
  11. Other $3,125 142 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,562 388 payments
  2. Education $49 5 payments
Products named General payments · program years 2019–2025
  1. UNITHROID $791 31 payments
  2. AFREZZA $717 42 payments
  3. SYNTHROID $584 27 payments
  4. Triptodur $528 27 payments
  5. TEPEZZA $346 6 payments
  6. ZOMACTON $306 13 payments
  7. Wegovy $287 13 payments
  8. SKYTROFA $270 11 payments
  9. SOMATULINE DEPOT $262 12 payments
  10. FENSOLVI $247 12 payments
  11. Other $4,141 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record